Crispr Therapeutics (CRSP)
NASDAQ:CRSP
Want to see CRSP full AI Analyst Report?
Ctx310
Hypertriglyceridemia, Homozygous Familial Hypercholesterolemia (Hofh), Hypercholesterolaemia, Dyslipidemias, Metabolic Disease, Severe Hypertriglyceridemia (Shtg), Cardiovascular, Lipid Disorder, Heterozygous Familial Hypercholesterolemia (Hefh), Mixed Hyperlipemia
Phase I
Recruiting
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
Mar 18, 2026
―
Ctx112
Myositis, Sle (Systemic Lupus), Inflammatory Myopathy, Idiopathic, Diffuse Cutaneous Systemic Sclerosis, Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis
Phase I
Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Mar 25, 2025
―
Ctx131
Acute Myeloid Leukemia, T Cell Lymphoma, B Cell Lymphoma
Phase I/II
Recruiting
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
Jun 21, 2024
―
Ctx001
Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hematological Diseases, Hemoglobinopathies
Phase III
Recruiting
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
Apr 07, 2022
―
Ctx001
Hemoglobinopathies, Beta-Thalassemia, Hematologic Diseases, Genetic Diseases, Inborn, Thalassemia
Phase III
Recruiting
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
Apr 07, 2022
―
Ctx130
T Cell Lymphoma
Phase I
Terminated
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)
Aug 04, 2020
―
Ctx130
Renal Cell Carcinoma
Phase I
Terminated
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)
Jun 16, 2020
―
Ctx120
Multiple Myeloma
Phase I
Terminated
A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma
Jan 24, 2020
―
Ctx001
Hemoglobinopathies, Genetic Diseases, Inborn, Beta-Thalassemia, Sickle Cell Disease, Hematologic Diseases, Thalassemia, Sickle Cell Anemia
Phase III
Enrolling By Invitation
A Long-term Follow-up Study in Participants Who Received CTX001
Dec 20, 2019
―
Ctx110
B-Cell Malignancy, Adult B Cell All, B-Cell Lymphoma, Non-Hodgkin Lymphoma
Phase I/II
Terminated
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Jul 22, 2019
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Crispr Therapeutics (CRSP) have in its pipeline
CRSP is currently developing the following drugs: Ctx310, Ctx112, Ctx131. These drug candidates are in various stages of clinical development as the company works toward FDA approval.